Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/125615
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Ginsenoside Rg3: Potential molecular targets and therapeutic indication in metastatic breast cancer |
Author: | Nakhjavani, M. Hardingham, J.E. Palethorpe, H.M. Tomita, Y. Smith, E. Price, T.J. Townsend, A.R. |
Citation: | Medicines, 2019; 6(1):17-1-17-20 |
Publisher: | MDPI |
Issue Date: | 2019 |
ISSN: | 2305-6320 2305-6320 |
Statement of Responsibility: | Maryam Nakhjavani, Jennifer E Hardingham, Helen M Palethorpe, Yoko Tomita, Eric Smith, Tim J Price and Amanda R Townsend |
Abstract: | Breast cancer is still one of the most prevalent cancers and a leading cause of cancer death worldwide. The key challenge with cancer treatment is the choice of the best therapeutic agents with the least possible toxicities on the patient. Recently, attention has been drawn to herbal compounds, in particular ginsenosides, extracted from the root of the Ginseng plant. In various studies, significant anti-cancer properties of ginsenosides have been reported in different cancers. The mode of action of ginsenoside Rg3 (Rg3) in in vitro and in vivo breast cancer models and its value as an anti-cancer treatment for breast cancer will be reviewed. |
Keywords: | Ginsenoside Rg3 breast cancer AQP-1 epimer angiogenesis |
Description: | Published: 23 January 2019 |
Rights: | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
DOI: | 10.3390/medicines6010017 |
Published version: | http://dx.doi.org/10.3390/medicines6010017 |
Appears in Collections: | Aurora harvest 4 Surgery publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_125615.pdf | Published version | 5.18 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.